PP
NVCR icon

Paloma Partners’s NovoCure NVCR Stock Holding History

Paloma Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,087
Closed -$241K – 1651
2021
Q2 		$241K Sell
1,087
-517
-32% -$101K ﹤0.01% 1438
2021
Q1 		$212K Buy
+1,604
New +$254K ﹤0.01% 1743
2020
Q3 		– Sell
-103,037
Closed -$6.11M – 2343
2020
Q2 		$6.11M Buy
+103,037
New +$6.78M 0.11% 235
2020
Q1 		– Sell
-15,640
Closed -$1.32M – 1817
2019
Q4 		$1.32M Sell
15,640
-34,462
-69% -$2.78M 0.02% 817
2019
Q3 		$3.75M Buy
+50,102
New +$4.01M 0.08% 212

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's NVCR Position: Q3 2021 in Review

Paloma Partners sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 1,087 shares — an estimated $241K sold.

Paloma Partners first reported a position in NVCR in Q3 2019 and held it in 5 quarters. The position peaked at $6.11M in Q2 2020. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

  • Paloma Partners reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
  • Paloma Partners sold 1,087 NovoCure shares in Q3 2021, an estimated $241K.
  • Paloma Partners first reported a position in NovoCure in Q3 2019 and held it in 5 quarters.
  • Paloma Partners's NovoCure position peaked at $6.11M in Q2 2020.
  • 317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Paloma Partners's 13F filing for Q3 2021, filed 15 Nov 2021.